News

Actinogen's Exciting Advances with Xanamem Unveiled in Study

Actinogen's Exciting Advances with Xanamem Unveiled in Study

Actinogen Medical's Breakthrough Publication on Xanamem

Actinogen Medical Limited (ASX: ACW) recently announced the publication of a significant peer-reviewed article entitled Clinical Pharmacology and Approach to Dose Selection of Emestedastat, a Novel Tissue Cortisol Synthesis Inhibitor for the Treatment of Central Nervous System Disease. This article, featured in the Clinical Pharmacology in Drug Development journal, highlights the promising findings regarding the daily oral dose of 10 mg of Xanamem, which is currently under investigation in late-stage clinical trials for treating Alzheimer's disease and major depressive disorder.

The Importance of Dose Selection

The review underscores the relevance of establishing the correct dosage for Xanamem, confirming that the ongoing clinical trials utilize a 10 mg daily dose. Early pharmacokinetic (PK) modeling suggested that a higher dosage of 20 mg could be more effective. However, subsequent positron emission tomography (PET) scans indicated that lower doses of 10 mg, or even 5 mg, could sufficiently inhibit the 11?-HSD1 enzyme, validating the current testing regime.

Clinical Findings on Cognitive Benefits

Participants in clinical studies with daily doses ranging from 5 mg to 20 mg have shown an overall cognitive improvement, particularly in attention and working memory, even without a direct dose-response correlation. This consistency reaffirms that for optimal therapeutic activity of Xanamem, the daily dosage should not exceed 10 mg.

Insights from Dr. Dana Hilt

Dr. Dana Hilt, Actinogen's Chief Medical Officer, expressed confidence in the dosage determined through rigorous clinical testing. She emphasized the critical nature of thorough pharmacological assessments in determining brain effects, assuring that the findings from the XanaCIDD phase 2a trial, which demonstrated positive impact on depressive symptoms at the 10 mg dosage, align with their expectations for the ongoing XanaMIA phase 2b/3 trial for Alzheimer's.

The Role of Cortisol in Brain Health

Actinogen Medical is focused on developing innovative treatments for neurological conditions linked to cortisol dysregulation. Elevated cortisol levels are implicated in cognitive decline and can adversely affect the brain's health. Actinogen's primary drug candidate, Xanamem, is designed to mitigate these effects by inhibiting cortisol synthesis specifically within the brain while preserving adrenal function, representing a novel approach in treating Alzheimer's and related disorders.

Clinical Trials Underway

The XanaMIA Phase 2b/3 clinical trial is structured as a double-blind, placebo-controlled examination involving 220 participants with mild to moderate Alzheimer's disease. These patients are administered Xanamem at a 10 mg daily dose or placebo while the study assesses its effectiveness at slowing disease progression. The primary endpoint utilized is the Clinical Dementia Rating scale-Sum of Boxes (CDR-SB), a respected measure in dementia studies. The trials are being conducted across multiple sites, with initial results expected from the first 100 participants soon.

Previous Successful Trials

The earlier XanaCIDD Phase 2a trial focused on individuals suffering from treatment-resistant depression. Results revealed notable improvements in depression symptoms following administration of the 10 mg dosage over a six-week period, building a solid foundation for the effectiveness of Xanamem.

About Actinogen Medical

Actinogen Medical, listed on the ASX under the ticker ACW, is a biotechnology company committed to addressing significant unmet medical needs with its innovative therapies. They are dedicated to developing treatments targeting the underlying causes of cognitive impairment and depression associated with prolonged cortisol exposure, combining scientific rigor with compassion to improve patient outcomes.

Frequently Asked Questions

What is Xanamem?

Xanamem, also known as emestedastat, is a novel therapy under investigation for its potential to treat conditions like Alzheimer's disease and major depressive disorder by inhibiting cortisol synthesis in the brain.

What were the findings from the recent publication on Xanamem?

The peer-reviewed publication confirms the effectiveness of a 10 mg daily dose of Xanamem in managing cognitive functions and emphasizes the importance of accurately determining dosage through rigorous clinical testing.

Who is leading the research behind Xanamem?

Actinogen Medical, principally led by Chief Medical Officer Dr. Dana Hilt, spearheads the research and development efforts surrounding Xanamem.

What is the current status of clinical trials for Xanamem?

Ongoing clinical trials, including the XanaMIA Phase 2b/3 trial, are assessing the safety and efficacy of Xanamem in patients with Alzheimer's disease, with results expected in upcoming years.

Is Xanamem approved for general use?

No, Xanamem is currently an investigational product and is not yet approved for use outside of clinical trials by regulatory authorities.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Rokt's 164% Growth Shows Checkout Ads Have Real Muscle

Updated Category News Views 116

Checkout screens have become valuable real estate, and Rokt is planting a flag right in the middle of them. The New York ecommerce technology company landed on Deloitte's 2026 Technology Fast 500 after posting 164% revenue growth from 2022 through 2025. That is a meaningful number, not decorative corporate confetti, especially in a digital-ad market where plenty of...

Continue Reading
Trucking Hub Bets on Faster MVR Checks Nationwide Today

Updated Category News Views 98

Driver paperwork is where plenty of supposedly modern fleet systems still go to die. Trucking Hub’s Nov. 18 launch of GetMVR.com takes a clean swing at that mess: an online platform for ordering Motor Vehicle Records in all 50 states, with instant reports available in 48. It is not glamorous software, and frankly that is why it may matter. Fleets do not lose sleep over...

Continue Reading
Marina del Rey's Travel Award Brings Fresh Attention

Updated Category News Views 56

A harbor town just got handed a useful little megaphone. On November 18, 2026, the Marina del Rey Tourism Board said Marina del Rey had been selected as a winner in Good Housekeeping's 2027 Travel Awards. That is not a quarterly earnings event, and nobody ought to dress it up as one. Still, in the visitor economy, recognition from a broad consumer publication can matter...

Continue Reading
WYBOT's New Robots Push Hands-Free Pool Care in Lyon

Updated Category News Views 64

A pool robot climbing out of the water to dock itself is the sort of demo that makes people stop mid-aisle at a trade show. WYBOT brought precisely that kind of attention-grabber to Piscine Global Lyon 2026, running November 17–20 at Eurexpo Lyon. The company is showing a broader lineup, but the M3 Pro is plainly the headline act: WYBOT calls it the world's first...

Continue Reading
Whole-House Remodels Need a Plan Before Any Finishes

Updated Category News Views 14

A remodel gets expensive the minute somebody falls in love with tile before checking what sits behind the wall. Adam Sherman’s central point in the HelloNation article is refreshingly unglamorous: treat the house as one working system before treating it as a collection of rooms crying out for cosmetic rescue. That sounds obvious until you see how often a kitchen...

Continue Reading
Somerville’s New Immersive Bet Has Room to Grow Locally

Updated Category News Views 74

A passcard, a hidden door, and 12,000 square feet of mischief have landed at Somernova. Edge of Elsewhere, the new flagship attraction from Boston-area creative studio Midnight Mansion, is open in Somerville’s Union Square as of November 18, 2026. It is part interactive art installation, part puzzle game, part physical story world. That sounds delightfully odd, which is...

Continue Reading
Linkind's Best Buy Push Tests Smart Outdoor Demand

Updated Category News Views 160

Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...

Continue Reading
Kids First Data Sharing Raises Pediatric Research Bar

Updated Category News Views 98

Thirty-eight thousand children’s records are not a headline gimmick; they are a serious argument for treating research data as an asset that must keep working after the first study ends. The Gabriella Miller Kids First Data Resource Center’s ten-year review, published in the September 2026 issue of The American Journal of Human Genetics, makes that argument with...

Continue Reading
illumine Targets Childcare Chain Control and Risk Gaps

Updated Category News Views 62

Expansion Gets Messy Before It Gets Impressive Childcare operators do not usually stumble because they forgot how to care for children; they stumble because the back office fractures as the network grows. One center handles fees one way, another lets enrollment leads work a different funnel, and headquarters discovers too late that its reports are arguing with each other....

Continue Reading
Specialty Chemicals Need Demand Before Capacity Bets

Updated Category News Views 83

Empty reactor space does not get filled because everybody suddenly loves reshoring. SOCMA's 2027 Contract Manufacturing Outlook makes that stubborn fact hard to dodge: nearly 70% of surveyed respondents expect North American manufacturing activity to rise over the next three years, yet 79.5% say stronger, more predictable customer demand is critical before future...

Continue Reading

Top 5 Most Recently Viewed Articles

Latin Metals Gears Up for Drilling at Organullo Gold Project

Updated Category News Views 176

Latin Metals Achieves Drilling Milestone for Organullo Gold Project Latin Metals Inc. (TSXV: LMS) is excited to announce that it has successfully secured a crucial permit for exploration drilling at the Organullo Gold Project. This approval is a significant step forward in their commitment to mineral exploration in Argentina. What the Drill Permit Means for Latin Metals...

Continue Reading
TheSushiDragon Partners with StreamerDap to Empower Creators

Updated Category News Views 444

TheSushiDragon Joins StreamerDap as Co-Owner In a groundbreaking move for the live streaming community, TheSushiDragon, a prominent Twitch creator, has officially entered an equity partnership with StreamerDap, a leading platform revolutionizing the sponsorship landscape for creators. This innovative partnership aims to enhance the creator experience, making sponsorships...

Continue Reading
Tariffs, Inflation Insights: What Lies Ahead for Markets

Updated Category News Views 198

Market Trends: Understanding Recent Developments The market landscape has shown itself to be quite dynamic recently. As US President Donald Trump indicates the possibility of increased tariffs, there remains a juxtaposition of hope and uncertainty in the air. While discussions of a potential peace agreement between Russia and Ukraine seem to be gaining momentum, this has...

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 239

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
Bloom Energy Partners with Oracle to Boost AI Infrastructure

Updated Category News Views 301

Bloom Energy and Oracle: A Strategic Collaboration Bloom Energy Corp (NYSE: BE) is experiencing a notable surge in its stock prices following a recent announcement that highlights a significant partnership with Oracle Corp (NYSE: ORCL). This new collaboration aims to utilize Bloom's innovative fuel cell technology to deliver onsite power solutions for selected Oracle...

Continue Reading